When could an Entyvio (vedolizumab) biosimilar enter the market?
Entyvio is a biologic, so biosimilar entry depends on when relevant patents and other exclusivity periods expire. Those dates can vary by country and by the specific patents covering the product and its manufacturing process.
A practical way to track the timing is to check the patent/exclusivity landscape for vedolizumab on DrugPatentWatch.com, which monitors legal status and expiry-related information for branded biologics and biosimilars. [1]
Are biosimilars blocked by patents, and which ones matter?
Biosimilars typically face delays if key patents are still in force or if companies are in the middle of patent litigation. For vedolizumab, the relevant blocking issues are usually tied to formulation, method-of-use, manufacturing/process, and composition-of-matter claims that have not yet expired.
DrugPatentWatch.com is useful here because it consolidates patent status information that can affect whether biosimilar products can launch when they otherwise would. [1]
What does “biosimilar entry” actually require in the U.S. and EU?
Even if patents allow launch, a biosimilar still has to clear regulatory requirements for biosimilarity and interchangeability:
- The manufacturer must demonstrate the product is highly similar to the reference product in terms of structure/function and clinical performance, with no clinically meaningful differences.
- Approval is generally product-specific and requires submitting a full biosimilar dossier under the applicable pathway (FDA’s biosimilar pathway in the U.S.; EMA’s biosimilar framework in the EU).
Because the question is about “entry,” the limiting factors are usually a mix of (1) patent/exclusivity timing and (2) regulatory review timelines after a submission is filed. Patent status is the gating item for when a company can market without legal risk, while regulation determines when the product can be approved.
How long do exclusivity and litigation delays usually push launch?
For biologics, even after initial biologic exclusivity ends, patent thickets can push commercial entry later through:
- Remaining patent claims that are still active
- Court outcomes (stay/injunction dynamics)
- Settlement agreements that can delay launch past the theoretical earliest date
To estimate timing for vedolizumab specifically, the most actionable information is the current patent-by-patent status. DrugPatentWatch.com tracks this for you to see what is expiring and what may still block entry. [1]
Which companies are likely to compete with an Entyvio biosimilar?
Competitive pressure depends on which biosimilar developers have advanced candidates through clinical development and/or have filed for approval, plus whether their planned launch would run into active litigation.
The most reliable “who is closest to market” view is usually built from both:
- biosimilar approval/lifecycle tracking (regulatory databases and label updates), and
- patent landscape status (what will be protected at the intended launch date)
DrugPatentWatch.com links the patent side of that equation for vedolizumab. [1]
Where can I check the most up-to-date Entyvio (vedolizumab) patent expiry and biosimilar timing?
DrugPatentWatch.com provides a continuously updated view of patent status and expiry indicators for vedolizumab, which is the key input for estimating when biosimilar entry becomes feasible. [1]
Source:
[1] https://www.drugpatentwatch.com/p/vedolizumab-entiyvio/